173 related articles for article (PubMed ID: 12088620)
1. Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections.
Pelak BA; Bartizal K; Woods GL; Gesser RM; Motyl M
Diagn Microbiol Infect Dis; 2002 Jun; 43(2):129-33. PubMed ID: 12088620
[TBL] [Abstract][Full Text] [Related]
2. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.
Hicks PS; Pelak B; Woods GL; Bartizal KF; Motyl M
Clin Microbiol Infect; 2002 Nov; 8(11):753-7. PubMed ID: 12445016
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.
Pelak BA; Woods GL; Teppler H; Friedland I; Bartizal K; Motyl M
J Chemother; 2002 Jun; 14(3):227-33. PubMed ID: 12120874
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of ertapenem against clinical bacterial isolates in 69 Spanish medical centers (E-test study)].
Gobernado M; Sanz-Rodríguez C; Villanueva R; Torroba L; Redondo E; González-Esteban J
Rev Esp Quimioter; 2007 Dec; 20(4):395-408. PubMed ID: 18563213
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
Pelak BA; Citron DM; Motyl M; Goldstein EJ; Woods GL; Teppler H
J Antimicrob Chemother; 2002 Nov; 50(5):735-41. PubMed ID: 12407133
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
Friedland I; Mixson LA; Majumdar A; Motyl M; Woods GL
J Chemother; 2002 Oct; 14(5):483-91. PubMed ID: 12462428
[TBL] [Abstract][Full Text] [Related]
11. [In vitro activity of ertapenem against strains isolated from diabetic foot infections].
Sotto A; Lemaire X; Jourdan N; Bouziges N; Richard JL; Lavigne JP
Med Mal Infect; 2008 Mar; 38(3):146-52. PubMed ID: 18191514
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Amsler KM; Davies TA; Shang W; Jacobs MR; Bush K
Antimicrob Agents Chemother; 2008 Sep; 52(9):3418-23. PubMed ID: 18591277
[TBL] [Abstract][Full Text] [Related]
13. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell KL; Gesser RM
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S119-25. PubMed ID: 12173120
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
Song JH; Ko KS; Lee MY; Park S; Baek JY; Lee JY; Heo ST; Kwon KT; Ryu SY; Oh WS; Peck KR; Lee NY
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):445-50. PubMed ID: 16949783
[TBL] [Abstract][Full Text] [Related]
15. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.
Casellas JM; Tomé G; Bantar C; Bertolini P; Blázquez N; Borda N; Couto E; Cudmani N; Guerrera J; Juárez MJ; López T; Littvik A; Méndez E; Notario R; Ponce G; Quinteros M; Salamone F; Sparo M; Sutich E; Vaylet S; Wolff L
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):527-37. PubMed ID: 14596972
[TBL] [Abstract][Full Text] [Related]
16. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
[TBL] [Abstract][Full Text] [Related]
17. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.
Dinubile MJ; Friedland I; Chan CY; Motyl MR; Giezek H; Shivaprakash M; Weinstein RA; Quinn JP
Eur J Clin Microbiol Infect Dis; 2005 Jul; 24(7):443-9. PubMed ID: 15990986
[TBL] [Abstract][Full Text] [Related]
18. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Johnson DM; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
[TBL] [Abstract][Full Text] [Related]
19. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
